Clovis Oncology, Inc. (NASDAQ:CLVS) – Research analysts at Oppenheimer Holdings issued their Q2 2017 EPS estimates for shares of Clovis Oncology in a research note issued to investors on Thursday. Oppenheimer Holdings analyst L. Cann anticipates that the biopharmaceutical company will earn ($1.18) per share for the quarter. Oppenheimer Holdings has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Clovis Oncology’s Q3 2017 earnings at ($1.13) EPS, Q4 2017 earnings at ($0.87) EPS, Q1 2018 earnings at ($0.67) EPS, Q2 2018 earnings at ($0.53) EPS, Q3 2018 earnings at ($0.53) EPS, Q4 2018 earnings at ($0.45) EPS, FY2018 earnings at ($2.17) EPS, FY2019 earnings at $2.07 EPS, FY2020 earnings at $3.55 EPS and FY2021 earnings at $4.97 EPS.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million during the quarter, compared to analyst estimates of $6.04 million.

ILLEGAL ACTIVITY WARNING: “Clovis Oncology, Inc. (CLVS) to Post Q2 2017 Earnings of ($1.18) Per Share, Oppenheimer Holdings Forecasts” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/clovis-oncology-inc-clvs-to-post-q2-2017-earnings-of-1-18-per-share-oppenheimer-holdings-forecasts/1398222.html.

CLVS has been the subject of a number of other reports. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $111.00 price objective (up from $72.00) on shares of Clovis Oncology in a research report on Tuesday, June 20th. Bank of America Corporation decreased their price objective on Clovis Oncology from $103.00 to $75.00 and set a “buy” rating for the company in a research report on Tuesday, June 20th. Janney Montgomery Scott raised Clovis Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday, June 20th. Morgan Stanley reaffirmed an “overweight” rating and set a $79.00 price objective on shares of Clovis Oncology in a research report on Tuesday, June 20th. Finally, Cann assumed coverage on Clovis Oncology in a research report on Thursday, June 22nd. They set a “market perform” rating for the company. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $72.40.

Clovis Oncology (NASDAQ CLVS) opened at 89.96 on Monday. The firm has a 50-day moving average price of $56.20 and a 200-day moving average price of $56.21. The firm’s market capitalization is $4.03 billion. Clovis Oncology has a one year low of $11.57 and a one year high of $94.30.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Monday, May 15th. The stock was sold at an average price of $47.39, for a total transaction of $142,170.00. Following the completion of the transaction, the insider now directly owns 203,583 shares of the company’s stock, valued at $9,647,798.37. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 9,000 shares of company stock valued at $495,690. 17.40% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in CLVS. Palo Alto Investors LLC increased its position in Clovis Oncology by 2.4% in the first quarter. Palo Alto Investors LLC now owns 3,894,963 shares of the biopharmaceutical company’s stock valued at $247,992,000 after buying an additional 90,875 shares during the last quarter. Vanguard Group Inc. increased its position in Clovis Oncology by 25.3% in the first quarter. Vanguard Group Inc. now owns 3,285,195 shares of the biopharmaceutical company’s stock valued at $209,169,000 after buying an additional 662,969 shares during the last quarter. State Street Corp increased its position in Clovis Oncology by 93.7% in the fourth quarter. State Street Corp now owns 2,141,663 shares of the biopharmaceutical company’s stock valued at $95,131,000 after buying an additional 1,035,917 shares during the last quarter. FMR LLC increased its position in Clovis Oncology by 271.4% in the first quarter. FMR LLC now owns 1,816,859 shares of the biopharmaceutical company’s stock valued at $115,679,000 after buying an additional 1,327,703 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in Clovis Oncology by 10,143.6% in the first quarter. Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company’s stock valued at $84,788,000 after buying an additional 1,318,669 shares during the last quarter. 90.67% of the stock is owned by institutional investors.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.